共 64 条
Defective thrombus formation in mice lacking coagulation factor XII
被引:550
作者:
Renné, T
Pozgajová, M
Grüner, S
Schuh, K
Pauer, HU
Burfeind, P
Gailani, D
Nieswandt, B
[1
]
机构:
[1] Univ Wurzburg, Inst Clin Biochem & Pathobiochem, D-97078 Wurzburg, Germany
[2] Univ Wurzburg, Klinikum Rudolf Virchow, Deutsche Forschungsgemeinschaft Res Ctr Expt Biom, D-97078 Wurzburg, Germany
[3] Univ Gottingen, Dept Gynecol & Obstet, D-37073 Gottingen, Germany
[4] Univ Gottingen, Inst Human Genet, D-37073 Gottingen, Germany
[5] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA
[6] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA
关键词:
D O I:
10.1084/jem.20050664
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Blood coagulation is thought to be initiated by plasma protease factor VIIa in complex with the membrane protein tissue factor. In contrast, coagulation factor XII ( FXII)-mediated fibrin formation is not believed to play an important role for coagulation in vivo. We used FXII-deficient mice to study the contributions of FXII to thrombus formation in vivo. Intravital fluorescence microscopy and blood flow measurements in three distinct arterial beds revealed a severe defect in the formation and stabilization of platelet-rich occlusive thrombi. Although FXII-deficient mice do not experience spontaneous or excessive injury-related bleeding, they are protected against collagen- and epinephrine-induced thromboembolism. Infusion of human FXII into FXII-null mice restored injury-induced thrombus formation. These unexpected findings change the long-standing concept that the FXII-induced intrinsic coagulation pathway is not important for clotting in vivo. The results establish FXII as essential for thrombus formation, and identify FXII as a novel target for antithrombotic therapy.
引用
收藏
页码:271 / 281
页数:11
相关论文